2016 |
676 |
1,436,444,910 |
1. eculizumab 10 mg/ml |
2018 (Ordinance no. 77, of 12/14/2018) |
Paroxysmal nocturnal hemoglobinuria |
717,149,490 |
1,307,172,609 |
91.0 |
2. galsulfase 1 mg/ml |
2018 (Ordinance no. 83, of 12/19/2018) |
Mucopolysaccharidosis type VI |
145,918,651 |
3. elosulfase alfa 1 mg/ml |
2018 (Ordinance no. 82, of 12/19/2018) |
Mucopolysaccharidosis type IVA (Morquio Syndrome A) |
107,462,354 |
4. galsulfase 2 mg/ml |
2017 (Ordinance no. 62, of 12/19/2017) |
Mucopolysaccharidosis type II |
83,442,677 |
5. alfagalsidase 1 mg/ml |
Not incorporated (decision not to incorporate Ordinance no. 56, of 11/23/2020) |
Fabry disease |
80,920,978 |
6. ataluren 250 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
55,633,789 |
7. agalsidase beta 35 mg |
Not incorporated (decision not to incorporate Ordinance No. 56, of 11/23/2020) |
Fabry disease |
37,717,391 |
8. metreleptin 11.3 mg |
Not incorporated and without registration with Anvisa |
Congenital or acquired generalized lipodystrophy |
32,054,438 |
9. lomitapide 10 mg |
Not incorporated (no evaluation by Conitec) |
Familial hypercholesterolemia |
23,927,105 |
10. human C1 esterase inhibitor 500 IU |
Not incorporated (no evaluation by Conitec) |
Hereditary angioedema type I and II |
22,945,735 |
2017 |
508 |
1,085,490,298 |
1. eculizumab 10 mg/ml |
2018 (Ordinance No. 77, of 12/14/2018) |
Paroxysmal nocturnal hemoglobinuria |
296,462,726 |
981,720,251 |
90.4 |
2. galsulfase 1 mg/ml |
2018 (Ordinance No. 83, of 12/19/2018) |
Mucopolysaccharidosis type VI |
176,252,001 |
3. elosulfase alfa 1 mg/ml |
2018 (Ordinance No. 82, of 12/19/2018) |
Mucopolysaccharidosis type IVA (Morquio Syndrome A) |
101,093,948 |
4. alfagalsidase 1 mg/ml |
Not incorporated (decision not to incorporate Ordinance No. 56, of 11/23/2020) |
Fabry disease |
100,592,156 |
5. ataluren 250 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
84,746,590 |
6. idursulfase 2 mg/ml |
2017 (Ordinance No. 62, of 12/19/2017) |
Mucopolysaccharidosis type II |
61,684,075 |
7. agalsidase beta 35 mg |
Not incorporated (decision not to incorporate Ordinance No. 56, of 11/23/2020) |
Fabry disease |
54,882,175 |
8. ataluren 1000 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
39,848,443 |
9. alpha-glucosidase 50 mg |
2019 (Ordinance No. 48, 10/16/2019) |
Pompe disease |
33,258,882 |
10. metreleptin 11.3 mg |
Not incorporated and without registration with Anvisa |
Congenital or acquired generalized lipodystrophy |
32,899,255 |
2018 |
332 |
1,495,905,549 |
1. eculizumab 10 mg/ml |
2018 (Ordinance No. 77, of 12/14/2018) |
Paroxysmal nocturnal hemoglobinuria |
478,746,855 |
1,364,024,905 |
91.2 |
2. galsulfase 1 mg/ml |
2018 (Ordinance No. 83, of 12/19/2018) |
Mucopolysaccharidosis type VI |
164,038,893 |
3. idursulfase 2 mg/ml |
2017 (Ordinance No. 62, of 12/19/2017) |
Mucopolysaccharidosis type II |
124,079,026 |
4. nusinersen 2.4 mg/ml |
2021 (Ordinance No. 26, of 6/1/2021) |
Spinal muscular atrophy 5q type II, diagnosed up to 18 months of age |
124,045,961 |
2018 |
332 |
1,495,905,549 |
5. elosulfase alfa 1 mg/ml |
2018 (Ordinance No. 82, of 12/19/2018) |
Mucopolysaccharidosis type IVA (Morquio Syndrome A) |
112,287,809 |
1,364,024,905 |
91.2 |
6. alfagalsidase 1 mg/ml |
Not incorporated (decision not to incorporate Ordinance No. 56, of 11/23/2020) |
Fabry disease |
105,496,952 |
7. ataluren 250 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
100,947,361 |
8. ataluren 1,000 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
55,002,927 |
9. agalsidase beta 35 mg |
Not incorporated (decision not to incorporate Ordinance No. 56, of 11/23/2020) |
Fabry disease |
53,825,639 |
10. alpha-glucosidase 50 mg |
2019 (Ordinance No. 48, 10/16/2019) |
Pompe disease |
45,553,481 |
2019 |
284 |
1,004,114,249 |
1. eculizumab 10 mg/ml |
2018 (Ordinance No. 77, of 12/14/2018) |
Paroxysmal nocturnal hemoglobinuria |
467,571,795 |
950,325,051 |
94.6 |
2. elosulfase alfa 1 mg/ml |
2018 (Ordinance No. 82, of 12/19/2018) |
Mucopolysaccharidosis type IVa (Morquio Syndrome A) |
190,076,099 |
3. alfagalsidase 1 mg/ml |
Not incorporated (decision not to incorporate Ordinance No. 56, of 11/23/2020) |
Fabry disease |
105,003,061 |
4. nusinersen 2.4 mg/ml |
2021 (Ordinance No. 26, of 6/1/2021) |
Spinal muscular atrophy 5q type II |
87,703,893 |
5. galsulfase 1 mg/ml |
2018 (Ordinance No. 83, of 12/19/2018) |
Mucopolysaccharidosis type VI |
54,288,525 |
6. metreleptin 11.3 mg |
Not incorporated and without registration with Anvisa |
Congenital or acquired generalized lipodystrophy |
21,533,960 |
7. eteplirsen 50 mg/ml |
Not incorporated and without registration with Anvisa |
Duchenne Muscular Dystrophy |
8,324,480 |
8. sebelipase alfa 2 mg/ml |
Not incorporated (no evaluation by Conitec) |
Lysosomal acid lipase deficiency |
6,308,632 |
9. brentuximab vedotin 50 mg |
2019 (Ordinance No. 12, of 3/11/2019) |
Hodgkin’s lymphoma cd30+ |
5,976,991 |
10. mercaptamine 75 mg |
Not incorporated and without registration with Anvisa |
Nephropathic cystinosis |
3,537,616 |
2020 |
678 |
592,320,679 |
1. eculizumab 10 mg/ml |
2018 (Ordinance No. 77, of 12/14/2018) |
Paroxysmal nocturnal hemoglobinuria |
220,640,260 |
484,460,069 |
81,8 |
2. ataluren 250 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
107,559,900 |
3. clozapine 100 mg |
2015 (Ordinance No. 3, of 3/9/2015) and 2016 (Ordinance No. 22, of 5/31/2016) |
Bipolar affective disorder and psychosis associated with Parkinson’s disease |
42,825,048 |
4. metreleptin 11.3 mg |
Not incorporated and without registration with Anvisa |
Congenital or acquired generalized lipodystrophy |
36,465,099 |
5. alpha-glucosidase 50 mg |
2019 (Ordinance No. 48, 10/16/2019) |
Pompe disease |
19,945,651 |
6. ataluren 1,000 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
19,580,225 |
7. ataluren 125 mg |
Not incorporated (no evaluation by Conitec) |
Duchenne Muscular Dystrophy |
15,212,043 |
8. mercaptamine 75 mg |
Not incorporated and without registration with Anvisa |
Nephropathic cystinosis |
10,014,300 |
9. sebelipase alfa 2 mg/ml |
Not incorporated (no evaluation by Conitec) |
Lysosomal acid lipase deficiency |
8,655,498 |
10. cerliponase alfa 30 mg/ml |
Under analysis by Conitec |
Neuronal ceroid lipofuscinosis type 2 |
3,562,045 |